Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13.
The US Food and Drug Administration recently defined the clinical term "bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer" as a disease state resistant to adequate bacillus Calmette-Guérin therapy. There is a significant lack of prognostication for this disease even in patients who have undergone early radical cystectomy. This study aimed to identify the clinical outcomes and prognostic factors in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer who underwent early radical cystectomy.
Data from a large-scale multicenter retrospective study included 2879 patients with highest-risk or high-risk non-muscle-invasive bladder cancer who received intravesical bacillus Calmette-Guérin induction therapy between January 2000 and December 2019. A total of 141 patients (4.3%) met the criteria for bacillus Calmette-Guérin-unresponsive disease, of whom 47 (33.3%) underwent early radical cystectomy. Prognostic factors for three clinical endpoints, namely, unresectable lesion-free survival, cancer-specific survival, and overall survival, were identified.
The highest-risk status at induction bacillus Calmette-Guérin was associated with short unresectable lesion-free survival (hazard ratio 7.85; P < 0.05), cancer-specific survival (hazard ratio 12.24; P < 0.05), and overall survival (hazard ratio 9.25; P < 0.01). Moreover, extravesical tumors (pathological T3 or T4) on the radical cystectomy specimens were associated with poor prognosis and were found at a higher rate in patients with the highest-risk status at induction bacillus Calmette-Guérin than in those with high-risk status (35.7% vs 21.2%).
The highest-risk status among the pre-bacillus Calmette-Guérin factors was associated with upstaging to extravesical tumors and poor prognosis despite early radical cystectomy procedures. Appropriate decision-making and the correct timing of radical cystectomy are vital to avoid treatment delays and improve outcomes.
美国食品和药物管理局最近将临床术语“卡介苗无反应性非肌肉浸润性膀胱癌”定义为对卡介苗治疗有足够反应的疾病状态。即使在接受早期根治性膀胱切除术的患者中,这种疾病的预后也存在很大的不确定性。本研究旨在确定接受早期根治性膀胱切除术的卡介苗无反应性非肌肉浸润性膀胱癌日本患者的临床结果和预后因素。
这项大规模多中心回顾性研究的数据来自于 2000 年 1 月至 2019 年 12 月期间接受膀胱内卡介苗诱导治疗的 2879 例高危或高风险非肌肉浸润性膀胱癌患者。共有 141 例(4.3%)符合卡介苗无反应疾病的标准,其中 47 例(33.3%)接受了早期根治性膀胱切除术。确定了三个临床终点(不可切除病变无复发生存、癌症特异性生存和总生存)的预后因素。
诱导卡介苗时的高危状态与不可切除病变无复发生存(风险比 7.85;P<0.05)、癌症特异性生存(风险比 12.24;P<0.05)和总生存(风险比 9.25;P<0.01)较短有关。此外,根治性膀胱切除标本上的膀胱外肿瘤(病理 T3 或 T4)与预后不良有关,在诱导卡介苗时处于高危状态的患者中比处于高风险状态的患者更常见(35.7%比 21.2%)。
在卡介苗前因素中,高危状态与膀胱外肿瘤的分期升高和预后不良有关,尽管进行了早期根治性膀胱切除术。适当的决策和根治性膀胱切除术的正确时机对于避免治疗延误和改善结局至关重要。